Verici Dx (LSE:VRCI) has marked a milestone in the first half of 2025 by generating initial revenues from its flagship product, Tutivia™, a diagnostic test for acute post-transplant rejection. The company secured £6.35 million in funding to support commercial expansion, extending its cash runway into the second half of 2026. Tutivia™ has received Medicare coverage, enabling broader adoption across transplant centers in the US. With commercial operations scaling up, Verici Dx anticipates a significant increase in testing volumes in H2 2025 and beyond.
Financially, the company continues to face challenges related to ongoing losses and cash flow pressures. While technical indicators are neutral, valuation remains weak due to negative earnings, highlighting the need for careful financial management during this growth phase.
About Verici Dx Plc
Verici Dx plc develops advanced clinical diagnostics for organ transplant patients, with a particular focus on kidney transplants. Its test portfolio leverages RNA sequencing technology to evaluate rejection risk and improve patient outcomes. Key offerings include Tutivia™, for detecting acute post-transplant rejection, and the Pre-Transplant Risk Assessment (PTRA) test, which is licensed to Thermo Fisher.
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.
Leave a Reply